Por: RTTNews Health September 12, 2023
Biopharmaceutical company AbbVie, Inc. () announced Tuesday top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg subcutaneous injection [SC] starting at week 12 and every 8 weeks thereafter) versus ustekinumab (STELARA, IV dose at week 0 and 90 mg SC every 8 weeks thereafter) through week 48 in patients with moderately to severely active... + full article
RTTNews USA Health September 29, 2023
AbbVie () announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more... + más
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System | The New York Times
AbbVie Posts an Earnings Beat but Forecast Misses as Competition Intensifies | MarketWatch
RTTNews USA Health August 28, 2023
Biopharmaceutical company AbbVie, Inc. () announced Monday that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for risankizumab (SKYRIZI, 1200 mg intravenous [IV] [induction dose] as well as... + más
High school scores and top performers from Thursday, March 9 | Orlando Sentinel
High school scores and top performers from Friday, March 24 | Orlando Sentinel
CBS News USA Entertainment February 10, 2023
From burgers, hot dogs, tacos, BBQ and wings, to salsas and cocktails, here are some tempting recipes from top chefs, cookbook authors and restaurateurs to go with watching the Big Game on Sunday, February 12. And whether you're rooting for the Chiefs or the Eagles, you... + más
NFL Playoff Scenarios | ABC News
Black Cookbooks To Help You Spice Things Up in the Kitchen This Holiday Season | The Root
MarketWatch USA Business February 09, 2023
International sales of Humira fell 26.5% from last year as the company lost patent protection in Europe and . However, revenue for the drug that treats Crohn’s disease grew 4.6% globally in the quarter to $5.58 billion, which was slightly above analysts’ estimates. said... + más
Cigna’s PBM Express Scripts Latest To Put Less Pricey Biosimilars Of Abbvie’s Humira On Preferred Drug List | Forbes
The New York Times USA Business January 28, 2023
In 2016, a blockbuster drug called Humira was poised to become a lot less valuable.The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug,... + más
Will More Women Patent Attorneys Lead To More Women Inventors? | Forbes
Samsung Beats IBM, Apple, Intel, Google For 2022 Patent Crown; 56% Of U.S. Patents Go To Foreign Firms | Forbes
ABC News USA Life January 06, 2023
The 30 women who will compete for ' heart on The Bachelor season 27 have been revealed.The 26-year-old tech executive from Anaheim Hills, California, will meet a group that includes four nurses, along with a few other medical professionals, a nanny from Vienna, a dancer and... + más
When is The Bachelor Season 27 out? Release date, contestants plus more | Newsweek
All the stars on 'Bachelor in Paradise' cast and when you last saw them | Newsweek
Forbes USA Tech December 05, 2022
Cigna’s pharmacy benefit manager Express Scripts will put “multiple biosimilar versions of Abbvie’s ... [+] expensive rheumatoid arthritis drug Humira in the “same position as the brand” on the PBM’s as a formulary in 2023. AbbVie's signature drug Humira is... + más
Cigna received millions of Medicare dollars based on invalid diagnoses, lawsuit claims | ABC News
How To Get Away With Corporate Murder: Unbundling And Disrupting Pharmacy Benefit Managers (Part 2) | Forbes
About iurex | Privacy Policy | Disclaimer |